Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Hodgkin Disease 7Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Hematologic Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasms 3Rhabdomyosarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Teratoma 1Solid Tumors 1Sarcoma 1Recurrence 1Myelodysplastic-Myeloproliferative Diseases 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1

Interventions

Vincristine 8X-Rays 6Temozolomide 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Cyclophosphamide 6Specimen Handling 5Irinotecan 5Nuclear Medicine Department, Hospital 4Biopsy 4Radiotherapy 3Radiation 3Dactinomycin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2Vinorelbine 2Proton Therapy 2LY3023414 2Ifosfamide 2Filgrastim 2Etoposide 2Doxorubicin 2Dexrazoxane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Filgrastim × 90 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
115 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡